Shots:

• DiaSorin to acquire Luminex for $37.00/ share in an all-cash transaction- with 23% premium based on closing stock price of Luminex on 24 Feb- 2021- making a total equity value of $1.8B
• The acquisition will boost DiaSorin's presence in the molecular diagnostics space in the US with the addition of Luminex's molecular diagnostics multiplexing technology and a portfolio
• Additionally- the acquisition will accelerate Luminex technology and solutions' penetration outside the US via DiaSorin's commercial and geographical reach

  Ref: PRNewswire | Image: Liminex